Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bayer Eylea injection gets Australian clearance
FDA-approved Eylea injection is a recombinant fusion protein, consisting of portions of human Vascular Endothelial Growth Factor (VEGF) receptors 1 and 2 extracellular domains fused to the Fc
FDA-approved Eylea injection is a recombinant fusion protein, consisting of portions of human Vascular Endothelial Growth Factor (VEGF) receptors 1 and 2 extracellular domains fused to the Fc
The joint venture will manage advanced-stage clinical trials in Russia of new pharmaceuticals and other products that will support regulatory approval of these products in Russia, the US
An international randomized double-blind placebo controlled Study COU-AA-302 included 1,088 patients who were randomized to receive Zytiga 1,000mg once daily plus prednisone 5mg administered twice daily or placebo
The cardiopatch study was conducted by researchers from the Faculty of Medicine of the Geneva University in collaboration with Ecole Polytechnique Federale de Lausanne (EPFL). Using a protein
According to the study, patients with more severe symptoms achieved a greater improvement following treatment with the ToleroMune T-cell vaccine than those on placebo (p=0.05). Therandomized, double-blind studywas
The Data from INSPIRE 2 HIV study showed that CYT107 administration can expand CD4 and CD8 T-cells while increasing the expression of gut homing molecules that may result
The Revitas revenue management solution allows pharmaceutical manufacturers to minimise the payment of erroneous claims for rebate and administrative fee payments by validating rebate claims for individual prescriptions.
Chronix has opened the laboratory in association with the First Bank & Trust of Brookings, South Dakota and the Area Development Corporation of Brookings, South Dakota. The Brookings
Notice of allowance has been granted to member patents of this family in the US, Japan, India, China, Korea, Mexico, Israel and Australia. BL-1020 is a novel, first
Lodotra is a proprietary, programmed-release formulation of low-dose prednisone and has received regulatory approval in Europe for the treatment of moderate to severe active rheumatoid arthritis (RA) when